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Common use of dietary supplements for bipolar
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Abstract
Background: Dietary supplements are taken by about half of Americans. Knowledge of dietary supplement use is
important because they may interact with prescription drugs or other supplements, cause adverse reactions
including psychiatric symptoms, or contain inherently toxic ingredients or contaminants. This study explores the
use of dietary supplements by patients with bipolar disorder in the US.
Methods: Data were obtained from an ongoing, naturalistic study of patients with bipolar disorder who received
pharmacological treatment as usual. The patients self-reported their daily mood, sleep, and medications taken,
including all drugs prescribed for bipolar disorder or that the patient felt impacted their mood. These included
other prescribed drugs, over-the-counter drugs and dietary supplements. Drugs that received premarketing approval
from the FDA were not included as dietary supplements. Patient demographics and daily medication use were
characterized.
Results: Data were available from 348 patients in the US who returned a mean 249.5 days of data. In addition to
prescribed psychiatric drugs, 101 of the 348 patients (29 %) used a dietary supplement for at least 7 days and 69
(20 %) used a supplement long term (for at least 50 % of days). Of the 101 supplement users, 72 (71.3 %) took
one supplement daily. The 101 patients tried over 40 different supplements, and the long-term users took 19 different
supplements. The most commonly taken supplements for both groups were fish oil, B vitamins, melatonin, and
multivitamins. Patients using supplements were more likely to be white (p < 0.001), older (p = 0.009), and ill for
more years (p = 0.025).
Conclusions: Many patients with bipolar disorder use dietary supplements in addition to prescribed drugs.
Physicians should obtain detailed information about all dietary supplements taken by patients with bipolar disorder.
Background
Dietary supplements, including vitamins, minerals,
herbals and botanicals, amino acids, enzymes, and other
products are used by about half the US population
(Gahche et al. 2011). Sales of dietary supplements generated
about US$32 billion in revenue in 2012 (Lariviere 2012;
NIH 2011) or about one tenth of that generated by
prescription drugs (Bartholow 2013). In 2008, the FDA
estimated there were 55,600 distinct dietary supplement
product labels manufactured by 1460 firms (Federal
Register 2009). The most popular supplements are
multivitamin/mineral products, taken by about one
third of Americans (Bailey et al. 2011; NIH 2013).
About three fourths of dietary supplements used by the
general public are selected by personal choice rather
than prescribed by a physician (Bailey et al. 2013). Less
is known about the use of dietary supplements by
people with mental illness, with studies reporting that
15–36 % take herbal and/or dietary supplements (Elkins
et al. 2005; Knaudt et al. 1999; Matthews et al. 2003;
Russinova et al. 2002; Wu et al. 2007).
Physician knowledge of patient use of dietary supple-
ments is important because of the potential for interac-
tions with prescription drugs or other supplements (Izzo
and Ernst 2009), potential adverse reactions including
psychiatric (Ernst 2003; Tsai et al. 2012), potential dangers
to special populations such as pregnant women, and the
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inherent toxicity of some ingredients (Kroll 2004). Only
about one third of patients, with and without mental ill-
ness, disclose the use of dietary supplements to their phys-
ician (Blendon et al. 2013; Elkins et al. 2005, Gardiner
et al. 2006; Keaton et al. 2009; Kennedy 2005; Matthews
et al. 2003; McCrea and Pritchard 2011; Mehta et al.
2008). Furthermore, the use of dietary supplements may
not be documented in a patient’s electronic medical record
(Staroselsky et al. 2008). This information may be particu-
larly important for patients with bipolar disorder since
most are prescribed polypharmacy (Bauer et al. 2013b; Lin
et al. 2006), and the risk of drug interactions increases
with the number of drugs taken (Goldberg et al. 1996;
Köhler et al. 2000). This study explores the use of dietary
supplements by patients with bipolar disorder who re-
ceived pharmacologic treatment as usual, based on daily
self-reported data.
Methods
All data were obtained from an ongoing, naturalistic, inter-
national study in which patients with bipolar disorder self-
reported daily their mood, sleep, and medications taken
(Bauer et al. 2009; Bauer et al. 2013a,b; Bauer et al. 2013c).
Study participants must have a diagnosis of bipolar disorder
by the DSM-IV criteria, be at least 18 years old, receive
pharmacological treatment as usual, and be willing to
use ChronoRecord self-reporting software daily on a
home computer. The study has minimal inclusion cri-
teria to better represent the heterogeneity of routine
clinical practice. The diagnosis of bipolar disorder was
made by the prescribing psychiatrist in a clinical inter-
view, and all patients received treatment as usual. All
participants were volunteers, primarily recruited by the
prescribing psychiatrist, and were informed about the
study prior to providing written informed consent. The
study was approved by the Ethical Committee of the
Medical Faculty of the Technische Universität Dresden,
and is in compliance with the Helsinki Declaration.
Patents received about a half hour of training, in per-
son or by telephone, before entering data.
The ChronoRecord database includes patients who
reside in several countries. However, because of inter-
national differences in the definition and regulation of
dietary supplements (Getman 2015), only data from
patients who reside in the US were included in this
analysis.
Data collection
The patients entered mood, sleep, medications, and sig-
nificant life events daily and weight weekly into the
ChronoRecord software. The daily self-ratings for mood
in ChronoRecord were previously validated with clin-
ician ratings on the Hamilton Depression Rating Scale
(HAMD) and the Young Mania Rating Scale (YMRS)
(Bauer et al., 2004, 2008). For rating mood, ChronoRecord
uses a 100-unit visual analog scale between the extremes
of mania and depression. Based upon the validation stud-
ies (Bauer et al., 2004, 2008), a mood entry less than 40
was considered depression, 40–60 euthymia, and greater
than 60 hypomania/mania. The depression ratings varied
from mild (entry of 20–39) to moderate-severe (entry of
0–19), and the mania ratings varied from hypomania
(entry of 61–80) to moderate-severe (entry of 81–100).
During patient training, a medication list was created
for each patient. The medication list includes all drugs
prescribed for bipolar disorder and any other medica-
tions that the patient felt impacted their mood, including
prescribed medications, over-the-counter (OTC) drugs,
and dietary supplements. The prescribed psychotropic
drugs were selected from a list in the software, displayed
by brand and generic names, including some well-
known supplements such as St. John’s wort. The patient
could add a drug or dietary supplement not included in
the software list and could modify the list of drugs taken
throughout the study period as needed. For each se-
lected drug, the pill strength was chosen from a list of
available strengths. Every day, for each drug, the patient
entered the total number of pills taken. Patients could
enter partial pills (1/4, 1/2, or 3/4) for tablets but not
capsules. If a drug was not taken, the patient entered 0
pills for that drug for that day. Data not entered on one
day could be entered at a later date. The software in-
cludes many error checking steps such as to prevent
entry for a future date.
Dietary supplements
The use of a dietary supplement was defined as taking
one supplement for at least 7 consecutive or non-
consecutive days during the study. Long-term use of a
dietary supplement was defined as taking one supple-
ment for at least 50 % of the study days. Drugs taken in
this study that were approved by the FDA, such as the
prescription drug Lovaza (omega-3-acid ethyl esters) or
OTC drug Unisom (doxylamine), were not included as
dietary supplements. The specific formulations or manu-
facturer of the dietary supplements were not obtained.
Statistical analysis
A minimum of 180 days of patient data was required for
inclusion in the analysis. The characteristics of patients
using and not using dietary supplements were compared.
Distributions of categorical variables were compared using
the Pearson’s two-sided asymptotic chi-squared test. Mean
values of continuous variables were compared using the
independent sample two-sided t test. Unequal variance
was assumed for all t tests. A p value of less than 0.05 was
considered statistically significant. SPSS version 22.0 was
used for all calculations.
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Results
Three hundred forty-eight patients in the US returned a
mean of 249.5 days of data. Of the 348 patients, 101
(29 %) used a dietary supplement and 69 (20 %) were
long-term users. The 101 users took a dietary supple-
ment for a mean of 66.5 % of the days (SD 33.6), while
the 69 long-term users took a dietary supplement for a
mean of 86.7 % of days (SD 14.9). The demographics of
the patients using and not using dietary supplements are
shown in Table 1. The patients using a dietary supple-
ment were older, white, and had more years of illness.
These conclusions did not change for the long-term
users. The patients using dietary supplements tried 40
different supplements, summarized in Table 2, with
long-term users taking 19 different supplements. Of the
supplement users (n = 101), the most commonly used
supplements were fish oil (n = 62), B vitamins (n = 25),
melatonin (n = 20), and multivitamins (n = 10). The same
supplements were most commonly used by the 69 long-
term users. Of the 101 supplement users, 72 (71.3 %)
were taking one supplement, 9 (8.9 %) were taking two
supplements, 20 (19.8 %) were taking three or more sup-
plements (10 taking three supplements and 10 taking
four or more). Of the 69 long-term users, 58 (84 %) were
taking one supplement, 6 (8.7 %) were taking two sup-
plements, and 5 (7.2 %) were taking three or more
Table 1 Patient demographics by using or not using dietary
supplements (N = 348)
Using
(N = 101)
Not using
(N = 247)
Test Value df P
Gender N (%) Χ2a 1.224 1 0.269
Male 29 (28.7) 57 (23.1)
Female 72 (71.3) 190 (76.9)
Diagnosis
N (%)
Χ2 2.489 2 0.288
Bipolar I 51 (51.0) 146 (60.0)
Bipolar II 41 (41.0) 83 (34.2)
NOS 8 (8.0) 14 (5.8)
Employment N (%) Χ2 0.831 2 0.660
Working full-time 49 (49.5) 112 (46.5)
Disabled 22 (22.2) 65 (27.0)
Others 28 (28.3) 64 (26.5)
Education
N (%)
Χ2 1.643 2 0.440
High school 7 (6.9) 27 (11.3)
Some college 30 (29.7) 73 (30.4)
College graduate 64 (63.4) 140 (58.3)
Marital status N (%) Χ2 0.412 2 0.814
Married 49 (50.0) 114 (48.3)
Single 34 (34.7) 90 (38.1)
Divorced 15 (15.3) 32 (13.6)
Ethnicity
N (%)
Χ2 14.875 1 <0.001
White 87 (86.1) 162 (65.6)
Non-white 14 (13.9) 85 (34.4)
Age mean age (SD) 41.8 (11.1) 38.4 (10.7) tb −2.627 180 0.009
aPearson’s chi-square, asymptotic two-sided
bEqual variances not assumed
Table 2 Dietary supplements taken by supplement users
(N = 101)
Type Supplement
Vitamins
Multivitamins
Vitamin B (folate, B6, B12, niacin, and
combination products)
Vitamin C
Vitamin D
Vitamin E
Minerals
Calcium
Chromium
Iron
Magnesium
Zinc
Herbs and nutritional
products
Artemisinin
Caffeine
DHEA
Echinacea
Fish oil
GABA
Garlic
Ginkgo
Glucosamine (with/without chondrotin)
Karaela
Melatonin
Methylsulfonylmethane (MSM)
Primrose oil
Probiotics
S-adenosylmethionine
St. John’s wort
Thyroid support products
Tryptophan
Tyrosine
Valerian
Weight loss products
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supplements (4 taking three supplements and 1 taking
five supplements).
All the patients taking a supplement were also taking
prescribed medications for bipolar disorder. As shown
in Table 3, there was no difference in the use of mood
stabilizers, antidepressants, antipsychotics, or benzodiaze-
pines between those using and not using supplements.
There was also no difference in reported symptoms of
mania or depression, including severe symptoms, between
those using and not using supplements. These conclusions
for medication use or mood reporting did not change for
the long-term users. Of the 69 long-term supplement
users, 51 were taking both a mood stabilizer and a supple-
ment. These 51 patients skipped taking mood stabilizers
on 5.2 % of the days and skipped taking supplements on
14.3 % of the days.
Discussion
Thirty percent of patients with bipolar disorder in this
study used dietary supplements in addition to prescribed
medications, with one in five patients using supplements
for the long term. Since this study did not include dietary
supplements used for other diseases or general health, the
results are likely to underestimate the total number of
patients using dietary supplements and the total sup-
plements taken. Nevertheless, these findings remain
consistent with prior research. About 13–52 % of adults
in the general population use dietary supplements and
prescription medications concurrently (Farina et al.
2014; Gardiner et al. 2006; McCrea and Pritchard 2011;
Qato et al. 2008), increasing when including vitamins
and minerals. The finding that dietary supplement use
was highest among older, white individuals was also
consistent with prior research (Bailey et al. 2011; Gahche
et al. 2011; Schaffer et al. 2003), although some studies also
report higher use in women than men (Gahche et al. 2011;
Gardiner et al. 2006; Schaffer et al. 2003).
In this study, patients using both dietary supplements
and mood stabilizers skipped taking the supplements
nearly three times more often than the mood stabilizers.
Similarly, in prior research, complementary and alterna-
tive medicines did not decrease adherence to medica-
tions prescribed for psychiatric disorders (Ennis 2014) or
general medical disorders (Cherniack 2011). The long-
term use of supplements had no impact on self-reported
mood symptoms, although individual supplements were
not analyzed. While the efficacy of dietary supplements
in the treatment of bipolar disorder is outside the scope
Table 3 Clinical characteristics by using or not using dietary supplements (N = 348)
Clinical characteristics Using dietary supplements
(N = 101)
Not using dietary supplements
(N = 247)
Test Value df P
Taking mood stabilizer N (%)a Χ2b 1.367 1 0.242
Yes 73 (72.3) 193 (78.1)
No 28 (27.7) 54 (21.9)
Taking antidepressant N (%)a Χ2 0.573 1 0.449
Yes 54 (53.5) 143 (57.9)
No 47 (46.5) 104 (42.1)
Taking antipsychotic N (%)a Χ2 0.340 1 0.560
Yes 41 (40.6) 92 (37.2)
No 60 (59.4) 155 (62.8)
Taking benzodiazepine N (%)a Χ2 0.016 1 0.901
Yes 26 (25.7) 62 (25.1)
No 75 (74.3) 185 (74.9)
Percentage of days depressed, mean (SD) 22.4 (22.4) 22.2 (23.6) tc −0.074 194 0.941
Percentage of days euthymic, mean (SD) 70.5 (24.3) 68.7 (26.8) t −0.584 204 0.560
Percentage of days manic, mean (SD) 7.1 (10.3) 9.0 (13.5) t 1.437 241 0.152
Percentage of days severely depressed, mean (SD) 8.3 (15.1) 7.4 (15.7) t −0.484 192 0.629
Percentage of days severely manic, mean (SD) 0.7 (2.4) 1.2 (4.7) t 1.380 330 0.169
Hospitalizations, mean number (SD) 2.1 (4.7) 1.9 (3.2) t −0.482 141 0.630
Age of onset, mean age (SD) 20.0 (8.2) 20.6 (9.7) t 0.545 198 0.586
Years of illness, mean years (SD) 21.9 (13.1) 18.45 (11.9) t −2.262 174 0.025
aTaking for 50 % or more days in study
bPearson’s chi-square, asymptotic two-sided
cEqual variances not assumed
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of this analysis, most review articles do not recommend
routine use of dietary supplements yet recognize that some
products have potential adjunctive benefit (Andreescu et al.
2008; Rakofsky and Dunlop 2014; Sagduyu et al. 2005;
Sarris et al. 2011). However, adverse effects of some sup-
plements may destabilize mood (Ernst 2003; Werneke
et al. 2006). For example, St. John’s wort, S-adenosyl-
methionine, and ginseng may induce mania (Andreescu
et al. 2008; Norelli and Xu 2014), supplements containing
serotonergic agents and stimulants may induce anxiety
(McCarthy et al. 2014), and melatonin may increase
daytime sleepiness (Werneke et al. 2006).
The findings of this study highlight the need to ask all
patients with bipolar disorder about their use of dietary
supplements. While the vast majority of dietary sup-
plements are taken safely by millions daily, many issues re-
main relating to the formulations of commercial dietary
supplements. Analytical testing of many commonly taken
dietary supplement products has found a wide deviation
between the ingredient amount stated on the label and the
measured amount (Lockwood 2011). For example, testing
of products purchased in US retail outlets have reported
potency between 62–184 % for fish oil EPA and DHA
(Kleiner et al. 2014) and between 9–146 % for vitamin D
(cholecalciferol) (LeBlanc et al. 2013). A recent investiga-
tion of top-selling store brands of herbal supplements at
four national retailers found that 80 % of the products did
not contain the herbs stated on their labels (O’Connor
2015). Differences in the purity and integrity of melatonin
products may contribute to the observed variations in ef-
fective doses and serum concentrations (de Rooij et al.
2014). Other quality concerns with dietary supplements
include adulterants not declared on the labels such as
prescription drugs, prohibited stimulants, prohormones,
anabolic steroids, chemical toxins or other chemical ingre-
dients (Geyer et al. 2008; Vaclavik et al. 2014), and micro-
bial contamination (Tournas 2009). Clinically relevant
amounts of T3 and/or T4 were present in nine out of ten
dietary or “thyroid support” supplements purchased online
(Kang et al. 2013). The supplements most frequently
adulterated are those advertised for the support of chronic
illnesses, obesity, and for athletes (Vaclavik et al. 2014).
Unlike drugs with a single active ingredient, supple-
ments are often complex mixtures of ingredients, often
of biological origin, and have multiple pharmacological
properties (Foster et al. 2005). As reviewed in detail else-
where, many dietary supplements used by patients with
bipolar disorder have the potential for pharmacokinetic
and pharmacodynamic interactions with prescribed drugs
or other supplements (Izzo and Ernst 2009; Gardiner et al.
2008). Pharmacokinetic interactions occur when one drug
impacts the absorption, distribution, metabolism, or excre-
tion of another drug, causing the blood level to increase or
decrease (Sandson et al. 2005). For example, St. John’s wort
may reduce effectiveness of benzodiazepines and metha-
done due to induction of cytochrome P450 3A4 enzyme
(Izzo and Ernst 2009). Pharmacodynamic interactions
occur when drugs act upon the same or related receptors,
causing additive or oppositional effects (Sandson et al.
2005). For example, St. John’s wort may interact with sero-
tonergic agents such as SSRI antidepressants to produce
serotonin syndrome (Izzo and Ernst 2009; Gardiner et al.
2008). In a literature review of 1491 drug-dietary supple-
ment interactions, prescription drugs that affect the central
nervous system or cardiovascular system were involved in
the most interactions with dietary supplements, and the
most frequently involved supplements were products con-
taining St. John’s wort, magnesium, calcium, iron, and
ginkgo (Tsai et al. 2012). Adverse events with dietary sup-
plements are underreported for several reasons including
the expectation that consumers will recognize and report
these to the FDA (GAO 2013). Furthermore, many dietary
supplements may not be included in software that checks
for drug interactions. The use of herbal products may also
result in abnormal laboratory test results (Dasgupta 2003).
Given their frequent use in bipolar disorder, it is also
important to recognize that the general public has many
misconceptions about dietary supplements. Many incor-
rectly assume that the FDA evaluates dietary supplement
products for safety and efficacy and approves product
advertisements (Ashar et al. 2008; Dodge et al. 2011;
Keaton et al. 2009; Pillitteri et al. 2008). Dietary supple-
ments and products labeled “natural” are often perceived
as being safer than OTC or prescription drugs (Dennehy
et al. 2005; Nichter and Thompson 2006). In a survey of
the general public (n = 1027), 29 % felt it was not neces-
sary to follow the recommended dosages for dietary sup-
plements, as compared with only 9 % for prescription
drugs (Gibson and Taylor 2005). Additionally, warning
labels on dietary supplement products intended to
decrease consumer perceptions of safety may have unin-
tended consequences and increase some consumer per-
ceptions of efficacy (Mason et al. 2007). Only one fourth
of users would stop using a supplement if the regulators
said it is ineffective (Blendon et al. 2013).
It is also difficult for patients to find high-quality informa-
tion about dietary supplements. Many pharmacists do not
have sufficient knowledge of dietary supplements to provide
counselling (Boon et al. 2009). Dietary supplements are
often purchased on the Internet, and many of these web
sites provide inadequate information to the consumer
(Monteith et al. 2013). In a survey of 1179 web sites for 13
common herbal products, only 8 % of retail sites contained
any safety information, and only 10.5 % recommended con-
sultation with a health-care professional (Owens et al. 2014).
There are limitations to this study. All data in the
study were self-reported, and daily access to a home
computer was required. The study included more females
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than males and did not include patients with bipolar
disorder who were not receiving treatment. However,
the demographic profile of the patients who use ChronoRe-
cord is similar to that in other studies of bipolar disorder
(Bauer et al. 2009; Bauer et al. 2012). Patient reluctance to
report dietary supplement use may also contribute to
underestimation of usage. We assume that most physicians
do not routinely ask patients about supplement use. It
is not known if use of the dietary supplement in this
study was initiated by the patient or recommended by
the physician. This database does not include medica-
tions taken for diseases other than bipolar disorder, so
the potential for interactions with dietary supplements
could not be accurately determined. Only US data were
included in this analysis, although dietary supplements
are commonly used worldwide. There are not enough
study participants to analyze for ethnic differences in
the use of dietary supplements, which have been noted
in prior research (Albright et al. 2012).
Conclusions
Patients with bipolar disorder commonly take dietary
supplements in addition to prescription medications.
About three out of ten patients used dietary supple-
ments, with two in ten of these taking supplements for
the long-term. The patients tried about 40 different sup-
plements, with fish oil, vitamin B preparations, multivi-
tamins, and melatonin taken most frequently. Dietary
supplements have the potential to interact with prescrip-
tion drugs and other supplements and to cause adverse
reactions. Many quality issues remain with formulations
of commercial dietary supplements. The physician
should obtain detailed information about all dietary sup-
plements taken by patients with bipolar disorder.
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